Literature DB >> 10371500

Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody.

F P Polack1, P G Auwaerter, S H Lee, H C Nousari, A Valsamakis, K M Leiferman, A Diwan, R J Adams, D E Griffin.   

Abstract

The severe disease atypical measles occurred when individuals immunized with a poorly protective inactivated vaccine contracted measles, and was postulated to be due to a lack of fusion-inhibiting antibodies. Here, rhesus macaques immunized with formalin-inactivated measles vaccine developed transient neutralizing and fusion-inhibiting antibodies, but no cytotoxic T-cell response. Subsequent infection with measles virus caused an atypical rash and pneumonitis, accompanied by immune complex deposition and an increase in eosinophils. Fusion-inhibiting antibody appeared earlier in these monkeys than in non-immunized monkeys. These data indicate that atypical measles results from previous priming for a nonprotective type 2 CD4 T-cell response rather than from lack of functional antibody against the fusion protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10371500     DOI: 10.1038/9473

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  45 in total

1.  Independence of measles-specific humoral and cellular immune responses to vaccination.

Authors:  Robert M Jacobson; Inna G Ovsyannikova; Robert A Vierkant; V Shane Pankratz; Gregory A Poland
Journal:  Hum Immunol       Date:  2012-03-03       Impact factor: 2.850

Review 2.  Measles virus, immune control, and persistence.

Authors:  Diane E Griffin; Wen-Hsuan Lin; Chien-Hsiung Pan
Journal:  FEMS Microbiol Rev       Date:  2012-03-13       Impact factor: 16.408

Review 3.  How innate immune mechanisms contribute to antibody-enhanced viral infections.

Authors:  Sukathida Ubol; Scott B Halstead
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

4.  Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following measles-mumps-rubella-II (MMR-II) vaccination.

Authors:  N Dhiman; I G Ovsyannikova; J E Ryan; R M Jacobson; R A Vierkant; V S Pankratz; S J Jacobsen; G A Poland
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

5.  More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Josephine McAuliffe; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

6.  Roles of macrophages in measles virus infection of genetically modified mice.

Authors:  B Roscic-Mrkic; R A Schwendener; B Odermatt; A Zuniga; J Pavlovic; M A Billeter; R Cattaneo
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response.

Authors:  Ianko D Iankov; Manoj Pandey; Mary Harvey; Guy E Griesmann; Mark J Federspiel; Stephen J Russell
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

8.  Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles.

Authors:  Judith J Ryon; William J Moss; Mwaka Monze; Diane E Griffin
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

9.  Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques.

Authors:  Chien-Hsiung Pan; Nitya Nair; Robert J Adams; M Christine Zink; Eun-Young Lee; Fernando P Polack; Manmohan Singh; Derek T O'Hagan; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

10.  Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in mice.

Authors:  M Jeff Bergen; Chien-Hsiung Pan; Catherine E Greer; Harold S Legg; John M Polo; Diane E Griffin
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.